'''Tiamenidine''' ([[British Approved Name|BAN]], [[United States Adopted Name|USAN]], [[International Nonproprietary Name|INN]], also known as '''thiamenidine''', '''Hoe 440''') is a [[imidazoline]] compound that shares many of the pharmacological properties of [[clonidine]]. It acts as a centrally-acting [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] and [[Alpha-2 adrenergic receptor|α<sub>2</sub> adrenergic receptor]] antagonist (with [[IC50]] 4.85 ''μ''M and 0.0091 ''μ''M, respectively).<ref>{{cite journal|last1=Timmermans|first1=PB|last2=de Jonge|first2=A|last3=Thoolen|first3=MJ|last4=Wilffert|first4=B|last5=Batink|first5=H|last6=van Zwieten|first6=PA|title=Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.|journal=Journal of Medicinal Chemistry|date=April 1984|volume=27|issue=4|pages=495–503|pmid=6142954|doi=10.1021/jm00370a011}}</ref> In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered [[cardiac output]].<ref>{{cite journal|last1=Roden|first1=DM|last2=Nadeau|first2=JH|last3=Primm|first3=RK|title=Electrophysiologic and Hemodynamic Effects of Chronic Oral Therapy With the Alpha 2-agonists Clonidine and Tiamenidine in Hypertensive Volunteers|journal=Clinical Pharmacology and Therapeutics|date=June 1988|volume=43|issue=6|pages=648–54|pmid=2897889|doi=10.1038/clpt.1988.90}}</ref> It was marketed (as tiamenidine hydrochloride) by [[Sanofi-Aventis]]<ref>{{cite web|title=Pharmaceutical and healthcare online databases. Tiamenidine Hydrochloride|url=http://drugs-about.com/drugs-s/sundralen.html|website=Drugs-About.com|accessdate=30 November 2015}}</ref> under the brand name '''Sundralen'''<ref>{{cite book|editor1-last=Ganten|editor1-first=D|editor2-last=Mulrow|editor2-first=Patrick J.|title=Pharmacology of Antihypertensive Therapeutics|date=2013|publisher=Springer-Verlag Berlin Heidelberg|location=[S.l.]|isbn=978-3-642-74211-8|page=880|edition=1st}}</ref> for the management of [[essential hypertension]].<ref name = "Zamboulis">{{cite journal|last1=Zamboulis|first1=C|last2=Hossmann|first2=V|last3=Dollery|first3=CT|last4=Eckert|first4=H|title=Tiamenidine, a Centrally Acting Antihypertensive Drug in Essential Hypertension [proceedings].|journal=British Journal of Clinical Pharmacology|date=October 1979|volume=8|issue=4|pages=390|pmid=508528}}</ref>
